Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 20 pp 20212—20225
LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma
Figure 4. Luciferase assay was used to validate targeting relationships. (A-C) Expression levels of LINC00265, miR-382-5p, SAT1 and VAV3 in osteosarcoma cells and osteoblasts. (D) Transfection efficiency of OE-LINC00265 and sh-LINC00265. (E, F) Luciferase assay confirmed that LINC00265 targeted miR-382-5p. (G) Transfection efficiency of miR-382-5p inhibitor and miR-382-5p mimic. (H-J) Luciferase assay confirmed that miR-382-5p targeted SAT1 and VAV3. *P < 0.05 vs. sh-NC or inhibitor-NC group; #P < 0.05 vs. OE-NC or mimic-NC group.